Arthur E. Frankel

A STING-activating nanovaccine for cancer immunotherapy

Min Luo, Hua Wang, Zhaohui Wang et al. · Nature Nanotechnology · 2017 · 889 citations

Life Sciences, Immunology, Oncology +14

Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients

Arthur E. Frankel, Laura Coughlin, Jiwoong Kim et al. · Neoplasia · 2017 · 712 citations · Full text

Life Sciences, Immunology, Oncology +17

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau et al. · EClinicalMedicine · 2021 · 275 citations · Full text

Medicine, Oncology, Pharmacology +14

CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies

Ugo Testa, Elvira Pelosi, Arthur E. Frankel · Biomarker Research · 2014 · 250 citations · Full text

Medicine, Hematology, Oncology +14

HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma

Kevin D. Courtney, Yuanqing Ma, Alberto Diaz de Leon et al. · Clinical Cancer Research · 2019 · 184 citations · Full text

Medicine, Oncology, Pharmacology +16